super ace withdrawal But alongside his stark warning of the threats facing Britain and its allies, Admiral Sir Tony Radakin said there would be only a “remote chance” Russia would directly attack or invade the UK if the two countries were at war. The Chief of the Defence Staff laid out the landscape of British defence in a wide-ranging speech, after a minister warned the Army would be wiped out in as little as six months if forced to fight a war on the scale of the Ukraine conflict. The admiral cast doubt on the possibility as he gave a speech at the Royal United Services Institute (Rusi) defence think tank in London. He told the audience Britain needed to be “clear-eyed in our assessment” of the threats it faces, adding: “That includes recognising that there is only a remote chance of a significant direct attack or invasion by Russia on the United Kingdom, and that’s the same for the whole of Nato.” Moscow “knows the response will be overwhelming”, he added, but warned the nuclear deterrent needed to be “kept strong and strengthened”. Sir Tony added: “We are at the dawn of a third nuclear age, which is altogether more complex. It is defined by multiple and concurrent dilemmas, proliferating nuclear and disruptive technologies and the almost total absence of the security architectures that went before.” He listed the “wild threats of tactical nuclear use” by Russia, China building up its weapon stocks, Iran’s failure to co-operate with a nuclear deal, and North Korea’s “erratic behaviour” among the threats faced by the West. But Sir Tony said the UK’s nuclear arsenal is “the one part of our inventory of which Russia is most aware and has more impact on (President Vladimir) Putin than anything else”. Successive British governments had invested “substantial sums of money” in renewing nuclear submarines and warheads because of this, he added. The admiral described the deployment of thousands of North Korean soldiers on Ukraine’s border alongside Russian forces as the year’s “most extraordinary development”. He also signalled further deployments were possible, speaking of “tens of thousands more to follow as part of a new security pact with Russia”. Defence minister Alistair Carns earlier said a rate of casualties similar to Russia’s invasion of Ukraine would lead to the army being “expended” within six to 12 months. He said it illustrated the need to “generate depth and mass rapidly in the event of a crisis”. In comments reported by Sky News, Mr Carns, a former Royal Marines colonel, said Russia was suffering losses of around 1,500 soldiers killed or injured a day. “In a war of scale – not a limited intervention, but one similar to Ukraine – our Army for example, on the current casualty rates, would be expended – as part of a broader multinational coalition – in six months to a year,” Mr Carns said in a speech at Rusi. He added: “That doesn’t mean we need a bigger Army, but it does mean you need to generate depth and mass rapidly in the event of a crisis.” Official figures show the Army had 109,245 personnel on October 1, including 25,814 volunteer reservists. Mr Carns, the minister for veterans and people, said the UK needed to “catch up with Nato allies” to place greater emphasis on the reserves. The Prime Minister’s official spokesman said Defence Secretary John Healey had previously spoken about “the state of the armed forces that were inherited from the previous government”. The spokesman said: “It’s why the Budget invested billions of pounds into defence, it’s why we’re undertaking a strategic defence review to ensure that we have the capabilities and the investment needed to defend this country.”

Trump encounters Senate GOP limits with failed Gaetz AG pushNone

Slash your bills with a phone call: 7 pro negotiating tipsA deal which could see the Elgin Marbles returned to Greece is “still some distance” away, George Osborne has signalled. The former Tory chancellor, now chairman of the British Museum, suggested Sir Keir Starmer had contributed to a warmer spirit of the negotiations over the famous ancient artworks. Greece has long called for the return of the Marbles, also known as the Parthenon sculptures, and maintains they were illegally removed from Athens’ acropolis during a period of foreign occupation. The British Museum – where they are currently on display – is forbidden by law from giving away any of its artefacts, and the Government has no plans to change the law to permit a permanent move. But under Mr Osborne’s leadership, the museum is negotiating the possibility of a long-term loan of the sculptures, in exchange for rolling exhibitions of famous artworks. No 10 has indicated the Prime Minister is unlikely to stand in the way of such a deal. Speaking on Political Currency, the podcast he hosts alongside former Labour politician Ed Balls, Mr Osborne said the museum was “looking to see if we can come to some arrangement where at some point some of the sculptures are in Athens, where, of course, they were originally sited”. He added: “And in return, Greece lends us some of its treasures, and we made a lot of progress on that, but we’re still some distance from any kind of agreement.” The Greek government has suggested negotiations with the museum have taken a warmer tone since Labour came to power in the summer. Mr Osborne appeared to concur with this view and praised Sir Keir’s hands-off approach, adding: “It is not the same as Rishi Sunak, who refused to see the Greek prime minister, if you remember, he sort of stood him up. “So it seems to me a more sensible and diplomatic way to proceed.” Kyriakos Mitsotakis, the Greek premier, discussed the Elgin Marbles with Sir Keir when they met on Tuesday morning at Downing Street, he said after returning to Athens. Mr Mitsotakis has signalled his government is awaiting developments on the negotiations. A diplomatic spat between the Greek leader and Mr Sunak emerged last year when the then-prime minister refused to meet his counterpart. Mr Mitsotakis had compared splitting the Elgin Marbles from those still in Athens to cutting the Mona Lisa in half. The marble statues came from friezes on the 2,500-year-old Parthenon temple and have been displayed at the British Museum for more than 200 years. They were removed by Lord Elgin in the early 19th century when he was British ambassador to the Ottoman Empire. Some of the remaining temple statues are on display in the purpose-built Acropolis Museum in Athens, and Greece has called for the collections to be reunited.

PHILADELPHIA , Dec. 5, 2024 /PRNewswire/ -- The Board of Directors of FS Credit Opportunities Corp. (the Fund) (NYSE: FSCO) announced the monthly distribution for December 2024 . The distribution of $0.06 per share will be paid on December 31, 2024 . Further information on the distribution is summarized in the charts below. The current annualized distribution rate equates to an annualized distribution yield 1 of 10.1% and 10.6%, respectively, based on the Fund's net asset value (NAV) and market price as of November 30, 2024 . The monthly distribution has been fully covered by the Fund's net investment income throughout 2024, and the Fund has generated an estimated total return on NAV of 12.75% and 33.1% on market price year-to-date through November 30, 2024 . The Fund has approximately $2.2 billion in assets under management and invests in event-driven credit, special situations, private capital solutions and other non-traditional credit opportunities. Month Ticker Fund Name Monthly Dividend December FSCO FS Credit Opportunities Corp. $0.06 The distribution will be made on the following schedule: Month Ex-Date Record Date Payable Date December December 23, 2024 December 23, 2024 December 31, 2024 The Fund pays regular monthly cash distributions to common shareholders at a level rate that may be adjusted from time to time. The amount of monthly distributions may be affected by numerous factors, including changes in portfolio and market conditions. Shareholders should not use the information provided here in preparing their tax returns. The Fund will send a Form 1099-DIV to shareholders for the calendar year that will tell them how to report these distributions for federal income tax purposes. Investors should consider, among other things, the investment objectives, risks, charges and expenses of the Fund carefully before investing. Investors can find the Fund's most recent reports and other filings on the Securities and Exchange Commission's EDGAR Database or on the Fund's website ( https://fsinvestments.com/fs-credit-opportunities-corp/ ). About FS Investments FS Investments is a global alternative asset manager dedicated to delivering superior performance and innovative investment and capital solutions. The firm manages over $82 billion in assets for a wide range of clients, including institutional investors, financial professionals and individual investors. FS Investments provides access to a broad suite of alternative asset classes and strategies through its best-in-class investment teams and partners. With its diversified platform and flexible capital solutions, the firm is a valued partner to general partners, asset owners and portfolio companies. FS Investments is grounded in its high-performance culture and guided by its commitment to building value for its clients, investing in its colleagues and giving back to its communities. The firm has more than 500 employees across offices in the U.S., Europe and Asia and is headquartered in Philadelphia. Contact Information: Investor Relations Joe Montelione joseph.montelione@fsinvestments.com Media Sarah Hilferty media@fsinvestments.com Forward Looking Statements Statements included herein may constitute "forward-looking" statements as that term is defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements with regard to future events or the future performance or operations of the Fund. Words such as "intends," "will," "expects," and "may" or similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions. Certain factors could cause actual results to differ materially from those projected in these forward-looking statements. Factors that could cause actual results to differ materially include changes in the economy, geopolitical risks, risks associated with possible disruption to the Fund's operations or the economy generally due to hostilities, terrorism, natural disasters or pandemics such as COVID-19, future changes in laws or regulations and conditions in the Fund's operating area, unexpected costs, the price at which the Fund's shares of common stock may trade on the New York Stock Exchange and such other factors that are disclosed in the Fund's filings with the Securities and Exchange Commission. The inclusion of forward-looking statements should not be regarded as a representation that any plans, estimates or expectations will be achieved. Any forward-looking statements speak only as of the date of this communication. Except as required by federal securities laws, the Fund undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Readers are cautioned not to place undue reliance on any of these forward-looking statements. 1 Annualized distribution yield reflects the current month's distribution per share annualized and divided by the estimated current month end net asset value (NAV) per share or market price per share; because annualized distribution yield is based on estimated current month end NAV, it is an estimate that is subject to change. View original content to download multimedia: https://www.prnewswire.com/news-releases/fs-credit-opportunities-corp-fsco-declares-distribution-for-december-2024-302324322.html SOURCE FS InvestmentsMilstein Siegel Launches New Website Following Update to Firm Name 12-14-2024 12:52 AM CET | Business, Economy, Finances, Banking & Insurance Press release from: Getnews / PR Agency: SubmitINme Image: https://www.globalnewslines.com/uploads/2024/12/1734096074.jpg Milstein Siegel, a Maryland-based law firm specializing in family law, men's rights, and divorce, has unveiled a new website to reflect its recent name change from Siegel Law. The firm's commitment to providing expert legal services remains unchanged, with the updated online presence serving to better represent its expanded leadership and continued dedication to client needs. Ellicott City, MD - December 13, 2024 - Milstein Siegel, formerly known as Siegel Law, known for providing family law services [ https://milsteinsiegel.com/family-law/ ] in Maryland, is proud to announce the launch of its new website, https://milsteinsiegel.com/ , following a significant update to the firm's name. This rebranding effort reflects the growth and evolution of the practice while maintaining its core focus on family law, men's rights, and divorce cases. The new website serves as a platform to showcase the firm's expertise and provide valuable resources to clients navigating complex legal matters. Milstein Siegel's expertise in family law encompasses a wide range of issues, including divorce, child custody, alimony, and property division. The firm has built a strong reputation for its advocacy in men's rights, addressing the unique challenges faced by fathers and husbands in family law matters. With a deep understanding of Maryland's legal environment, Milstein Siegel continues to provide strategic and compassionate representation to clients during some of life's most challenging moments. The new website features detailed information about the firm's practice areas, attorney profiles, and educational resources to help clients better understand their legal options. It also includes a user-friendly interface that allows potential clients to easily reach out for consultations and stay informed about the latest developments in family law. By leveraging technology and maintaining a strong online presence, Milstein Siegel aims to bridge the gap between complex legal concepts and their clients' needs for clear, actionable information. The firm's commitment to staying at the forefront of legal trends and technologies ensures that clients receive the most up-to-date and effective representation possible. As Milstein Siegel embarks on this new chapter, the firm remains dedicated to its core values of integrity, professionalism, and client-centered service. The new website and updated name reflect not only the firm's evolution but also its unwavering commitment to achieving the best possible outcomes for its clients in family law matters. For more information about Milstein Siegel or to schedule a consultation, interested parties are encouraged to visit the new website at https://milsteinsiegel.com/ . The firm itself is located at 6011 University Blvd. Suite 250, Ellicott City, MD 21043 and can be reached at (443) 230-4674. Media Contact Company Name: Milstein Siegel Contact Person: Michael Milstein Email: Send Email [ http://www.universalpressrelease.com/?pr=milstein-siegel-launches-new-website-following-update-to-firm-name ] Phone: (443) 230-4674 Address:6011 University Blvd. Suite 250 City: Ellicott City State: Maryland Country: United States Website: https://milsteinsiegel.com/ This release was published on openPR.

B.C. premier says feds and premiers have right-left strategy to tackle Trump tariffs

CRENESSITY, the first new treatment available in 70 years to the classic congenital adrenal hyperplasia (CAH) community, offers a paradigm-shifting treatment approach FDA approval supported by data from the largest-ever clinical trial program in pediatric and adult patients with classic CAH CRENESSITY is expected to be commercially available in approximately one week Rare Pediatric Disease Priority Review Voucher granted in connection with approval SAN DIEGO , Dec. 13, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) today announced the U.S. Food and Drug Administration has approved CRENESSITYTM (crinecerfont) capsules and oral solution as an adjunctive treatment to glucocorticoid replacement to control androgens in adult and pediatric patients four years of age and older with classic congenital adrenal hyperplasia (CAH), a rare, serious and lifelong genetic condition involving the adrenal glands. CRENESSITY, a potent and selective oral corticotropin-releasing factor type 1 receptor (CRF 1 ) antagonist, is the first and only classic CAH treatment that directly reduces excess adrenocorticotropic hormone (ACTH) and downstream adrenal androgen production, allowing for glucocorticoid dose reduction. It is a breakthrough in the treatment landscape for classic CAH. "For the last three decades, Neurocrine Biosciences, together with our late founder, Wylie W. Vale , has conducted groundbreaking research uncovering the critical role of corticotropin-releasing factor and its receptor, CRF 1 , in the pathophysiology of congenital adrenal hyperplasia," said Kyle W. Gano , Ph.D., Chief Executive Officer, Neurocrine Biosciences. "The approval of CRENESSITY is a significant milestone for the CAH community, and we are grateful to the individuals who participated in our clinical trials, including their families and caregivers, and to the clinical investigators who helped advance a new therapy and class of medicines." "Patients and families struggle to achieve balance between managing the symptoms of CAH and the side effects or complications of treatment with high-dose steroids, which may impact quality of life," said Dina Matos , Executive Director, CARES Foundation. "We are grateful to Neurocrine Biosciences for engaging with our community throughout the drug development process to understand our needs and ultimately providing this new medication that can help reduce excess adrenal androgens and the need for high-dose steroid treatment for individuals living with CAH." CRENESSITY is expected to be commercially available in approximately one week. The medication will be provided through PANTHERx Rare, a specialty pharmacy, to centralize and simplify CRENESSITY prescription fulfillment. Neurocrine Biosciences is committed to supporting patients in obtaining treatment with CRENESSITY by offering Neurocrine Access Support, a free, comprehensive assistance program created for patients, caregivers and healthcare providers. It offers a range of options to make sure patients have everything they need to begin and continue taking CRENESSITY. A dedicated Care Coordinator, backed by a team, is available to help patients and caregivers navigate the insurance process and identify appropriate financial assistance options. Most patients will pay $10 or less per month for CRENESSITY*. For more information, visit www.NBIacces.com/crenessity or call 1-855-CRNSITY (276-7489) Monday-Friday 8 am-8 pm ET . *Additional terms and conditions apply. CAHtalyst TM Clinical Program Overview: The FDA approval is supported by the largest-ever clinical trial program of classic CAH, the CAHtalyst Pediatric and Adult Phase 3 global registrational studies. CAHtalyst Phase 3 data results in pediatric and adult patients with classic CAH were published in The New England Journal of Medicine . "The clinical results across both CAHtalyst studies support the efficacy and safety profile of CRENESSITY and its ability to reduce the overproduction of adrenal androgens, allowing for a meaningful reduction in glucocorticoid dosage, while maintaining or enhancing control of these androgens," said Richard Auchus , M.D., Ph.D., Professor, University of Michigan Health, Principal Investigator. "Chronic treatment with supraphysiologic glucocorticoids can cause a number of short- and long-term health consequences, such as obesity, hypertension and osteoporosis, so the ability for patients with CAH to lower their glucocorticoid dose to a more physiologic level can have profound benefits." In both CAHtalyst studies, CRENESSITY enabled lower steroid doses and decreased androgen levels. Phase 3 CAHtalyst Pediatric Study: The CAHtalyst Pediatric study met its primary endpoint, with CRENESSITY significantly decreasing androstenedione levels from baseline to Week 4 versus patients taking placebo who experienced a substantial increase in androstenedione levels. Children taking CRENESSITY were also able to significantly reduce their GC doses at Week 28 while maintaining or improving androgen levels, a key secondary endpoint. Children taking CRENESSITY saw approximately four times greater reduction in androstenedione compared with those taking placebo. Approximately four times greater steroid dose reduction in children taking CRENESSITY was seen compared with those taking placebo. Children taking CRENESSITY saw approximately 12 times greater reduction in 17-hydroxyprogesterone (17-OHP) compared with those taking placebo. Headache, abdominal pain, fatigue, nasal congestion and nosebleed were the most common adverse drug reactions (ADRs) among the pediatric population treated with CRENESSITY. Most side effects were temporary and mild to moderate in severity. Phase 3 CAHtalyst Adult Study: The CAHtalyst Adult study met its primary endpoint with CRENESSITY enabling significant GC dose reductions at Week 24 (while maintaining or improving baseline androstenedione levels) and key secondary endpoint of decreasing androstenedione levels at Week 4. A significantly higher number of patients taking CRENESSITY (63%) achieved a GC dose in the physiologic range while androstenedione was maintained or improved compared with patients taking placebo (18%). Approximately two times greater steroid dose reduction was seen in people taking CRENESSITY compared with those taking placebo. People taking CRENESSITY saw an eight times greater reduction in androstenedione compared with those taking placebo. People taking CRENESSITY saw a 37 times greater reduction in 17-OHP compared with those taking placebo. Fatigue, headache, dizziness, joint pain, back pain, decreased appetite and muscle pain were the most common ADRs in the CRENESSITY treatment group. Most side effects were temporary and mild to moderate in severity. CRENESSITY was well tolerated with few treatment-related adverse events in both CAHtalyst studies. Pediatric and adult patients taking CRENESSITY had no treatment-related serious adverse events. Adrenal insufficiency and crisis are risks of living with CAH that CRENESSITY does not address and can occur when a patient's GC dose is too low. In the CAHtalyst Pediatric study, there were no cases of adrenal crisis among patients taking CRENESSITY or placebo. In the CAHtalyst Adult study, two patients (1.6%) taking CRENESSITY experienced adrenal crisis. No patients on placebo experienced adrenal crisis. However, one patient (1.7%) on placebo experienced adrenal insufficiency. Patients should work with their healthcare provider to manage GC dosing while taking CRENESSITY. For more information about CRENESSITY, visit Crenessity.com . About Congenital Adrenal Hyperplasia Congenital adrenal hyperplasia (CAH) is a rare genetic condition that results in an enzyme deficiency that alters the production of adrenal steroid hormones, such as cortisol, aldosterone and adrenal androgens, which are essential for life. Approximately 95% of CAH cases are caused by variants of the CYP21A2 gene that leads to deficiency of the enzyme 21-hydroxylase (21-OH). Severe deficiency of this enzyme leads to an inability of the adrenal glands to produce enough cortisol and, in approximately 75% of cases, aldosterone. Because individuals with CAH are still able to produce androgens, the unused precursors that would normally be used to make cortisol instead result in the production of excess amounts of androgens. If left untreated, CAH can result in salt wasting, dehydration and even death. Historically, exogenous glucocorticoids (GCs) have been used not only to correct the endogenous cortisol deficiency, but doses used are higher than cortisol replacement needed (supraphysiologic) to lower the levels of adrenocorticotropic hormone (ACTH) and adrenal androgens. However, GC treatment at high doses has been associated with serious and significant complications of steroid excess, including metabolic issues such as weight gain and diabetes, cardiovascular disease and osteoporosis. Additionally, long-term treatment with high-dose GCs may have psychological and cognitive impact, such as changes in mood and memory. Adrenal androgen excess has been associated with abnormal bone growth and development in pediatric patients, female health problems such as excess facial hair growth and menstrual irregularities, testicular rest tumors in males and fertility issues in both sexes. About The CAHtalystTM Studies The Phase 3 CAHtalystTM global registrational studies were designed to evaluate the safety, efficacy and tolerability of CRENESSITY in children and adults with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. The CAHtalyst studies were the largest-ever clinical trial program in classic CAH, including 285 pediatric and adult patients. The CAHtalyst Pediatric study included 103 pediatric patients aged four to 17 years. The study tested two questions. The first question evaluated whether four weeks of CRENESSITY treatment could improve androgen control. The second question evaluated whether an additional 24 weeks of CRENESSITY treatment enabled customized glucocorticoid (GC) down-titration while androstenedione levels were maintained or improved. The CAHtalyst Adult study included 182 adult patients aged 18 to 58 years. Similarly, the first question of the study evaluated whether four weeks of CRENESSITY treatment could improve androgen control, and the second question evaluated whether an additional 20 weeks of CRENESSITY treatment enabled GC reduction to physiologic range while androstenedione levels were maintained or improved. Data from the CAHtalyst Phase 3 studies supported approval of CRENESSITY by the U.S. Food and Drug Administration in December 2024. The open-label extension treatment portions of both studies are ongoing. About CRENESSITYTM (crinecerfont) CRENESSITYTM is a potent and selective, oral corticotropin-releasing factor type 1 receptor (CRF 1 ) antagonist developed to reduce and control excess adrenocorticotropic hormone (ACTH) and adrenal androgens through a non-glucocorticoid (GC) mechanism for the treatment of classic congenital adrenal hyperplasia (CAH). Antagonism of CRF 1 receptors in the pituitary has been shown to decrease ACTH levels, which in turn decreases the production of adrenal androgens and potentially the symptoms associated with CAH. The robust clinical study data demonstrate that lowering adrenal androgen levels with CRENESSITY enables lower, more physiologic dosing of GCs to replace missing cortisol. CRENESSITY comes in capsules and an oral solution. The capsule formulation is available in 50 mg and 100 mg doses. The oral solution is available as a 50 mg/mL strength formulation. For adults 18 years and older, the recommended dosage is 100 mg twice daily taken orally with a meal. For pediatric patients four to 17 years of age weighing less than 55 kg (121 lbs), the recommended dosage is based on body weight and is administered twice daily, taken orally with a meal. For pediatric patients weighing more than 55 kg (121 lbs), the recommended dosage is 100 mg twice daily taken orally with a meal. Healthcare providers can work with patients to determine the appropriate formulation for use depending on patient needs. Patients receiving CRENESSITY should continue GC therapy for cortisol replacement. Important Information Approved Uses CRENESSITY (crinecerfont) is a prescription medicine used together with glucocorticoids (steroids) to control androgen (testosterone-like hormone) levels in adults and children 4 years of age and older with classic congenital adrenal hyperplasia (CAH). IMPORTANT SAFETY INFORMATION Do not take CRENESSITY if you: Are allergic to crinecerfont, or any of the ingredients in CRENESSITY. CRENESSITY may cause serious side effects, including : Allergic Reactions. Symptoms of an allergic reaction include tightness of the throat, trouble breathing or swallowing, swelling of the lips, tongue, or face, and rash. If you have an allergic reaction to CRENESSITY, get emergency medical help right away and stop taking CRENESSITY. Risk of Sudden Adrenal Insufficiency or Adrenal Crisis With Too Little Glucocorticoid (Steroid) Medicine. Sudden adrenal insufficiency or adrenal crisis can happen in people with congenital adrenal hyperplasia who are not taking enough glucocorticoid (steroid) medicine. You should continue taking your glucocorticoid (steroid) medicine during treatment with CRENESSITY. Certain conditions such as infection, severe injury, or shock may increase your risk for sudden adrenal insufficiency or adrenal crisis. Tell your healthcare provider if you get a severe injury, infection, illness, or have planned surgery during treatment. Your healthcare provider may need to change your dose of glucocorticoid (steroid) medicine. Before taking CRENESSITY, tell your healthcare provider about all of your medical conditions, including if you are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed. Tell your healthcare provider about all the medicines you take , including prescription and over-the counter medicines, vitamins, and herbal supplements. The most common side effects of CRENESSITY in adults include tiredness, headache, dizziness, joint pain, back pain, decreased appetite, and muscle pain. The most common side effects of CRENESSITY in children include headache, stomach pain, tiredness, nasal congestion, and nose bleeds. These are not all the possible side effects of CRENESSITY. Call your healthcare provider for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch at www.fda.gov/medwatch or call 1-800-FDA-1088. Dosage Forms and Strengths: CRENESSITY is available in 50 mg and 100 mg capsules and as an oral solution of 50 mg/mL. Please see full Prescribing Information About Neurocrine Biosciences, Inc. Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids,* as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com , and follow the company on LinkedIn , X (formerly Twitter) and Facebook . (*in collaboration with AbbVie) The NEUROCRINE BIOSCIENCES Logo Lockup and YOU DESERVE BRAVE SCIENCE are registered trademarks of Neurocrine Biosciences, Inc. CRENESSITY and CAHtalyst are trademarks of Neurocrine Biosciences, Inc. Forward-Looking Statements In addition to historical facts, this press release contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements regarding the potential benefits to be derived from CRENESSITY for the treatment of classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency; the value and benefits CRENESSITY brings to patients with CAH; the ability of Neurocrine Biosciences to ensure patients have access to CRENESSITY; and whether the results from our clinical trials of CRENESSITY are indicative of real-world results. Factors that could cause actual results to differ materially from those stated or implied in the forward-looking statements include, but are not limited to, the following: risks and uncertainties associated with Neurocrine Biosciences' business and finances in general, as well as risks and uncertainties associated with the commercialization of CRENESSITY; whether CRENESSITY receives adequate reimbursement from third-party payors; the degree and pace of market uptake of CRENESSITY; risks and uncertainties relating to competitive products and technological changes that may limit demand for CRENESSITY; risks associated with the Company's dependence on third parties for development and manufacturing activities related to CRENESSITY, and the ability of the Company to manage these third parties; risks that additional regulatory submissions for CRENESSITY or other product candidates may not occur or be submitted in a timely manner; risks that the FDA or other regulatory authorities may make adverse decisions regarding CRENESSITY; risks that post-approval CRENESSITY commitments or requirements may be delayed; risks that CRENESSITY may be precluded from commercialization by the proprietary or regulatory rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; risks and uncertainties relating to competitive products and technological changes that may limit demand for CRENESSITY; and other risks described in the Company's periodic reports filed with the Securities and Exchange Commission, including without limitation the Company's quarterly report on Form 10-Q for the quarter ended September 30, 2024 . Neurocrine Biosciences disclaims any obligation to update the statements contained in this press release after the date hereof other than required by law. © 2024 Neurocrine Biosciences, Inc. All Rights Reserved. CP-CFT-US-0070 12/2024 SOURCE Neurocrine Biosciences, Inc.MADRID (AP) — Spanish King Felipe VI used his traditional Christmas Eve speech to remember the victims of the catastrophic Valencia flash floods , and urged the country to remain calm while addressing hot-button issues such as immigration and housing affordability. In a pre-recorded speech that usually reviews the year's most relevant issues, Felipe said Spain “must never forget the pain and sadness" the floods caused. The Oct. 29 floods killed more than 225 people in eastern Spain, damaging countless homes and leaving graveyards of cars piled on top of each other. In some towns, the heavy downpours that caused the floods dropped as much as a year's worth of rain in just eight hours. In early November, as Spaniards' shock at the wreckage turned into frustration, a political blame game began, directed especially at regional authorities who failed to send timely emergency alerts to cell phones on the day of the floods. The frustration of residents in hard-hit Paiporta near Valencia was on display when people tossed mud and shouted insults at the king and government officials in early November when they made their first visit to the town. “We have seen — and understood — the frustration, the pain, the impatience, the demands for greater and more effective coordination," Felipe said about how the disaster was managed. He also addressed the country's housing crunch and high rents, which have become a leading concern in the southern European country that is the eurozone's fourth-largest economy. Fast-rising rents are especially acute in cities like Barcelona and Madrid, where incomes have failed to keep up, especially for younger people in a country with chronically high unemployment. Felipe urged that “all the actors involved reflect” and "listen to each other” so that they facilitate bringing access to housing under “affordable conditions.” Spain's immigration debate should keep in mind the country's European partners and immigrants' countries of origin, Felipe said, warning that “the way in which we are able to address immigration ... will say a lot in the future about our principles and the quality of our democracy.” Felipe said Spain needed to remain calm in the public sphere, even in the face of a “sometimes thunderous” contest in its politics.

AP Sports SummaryBrief at 6:58 p.m. ESTTottenham joins list of top Premier League teams to lose at Bournemouth after Huijsen winnerIjesa youths on the umbrella of a group, Omo Owa, Omo Ekun Youth of Ijesaland, has urged kingmakers in Ilesa to be fair in handling the process of selecting new Owa Obokun of Ijesaland. Addressing journalists in Ilesa, the President of the group, Chief Babatunde Aguntasolo, reminded the kingmakers that it was taboo for them to have preferred or anointed candidates(s), among contestants for the stool. Aguntasolo, subsequently demanded a fair and just process that would allow interested princes regardless of their financial strengths, to via for the stool, and if considered good enough to be made new Owa Obokun Adimula. “You will agree with me that the throne can not remain vacant, all eyes are on the next ruling house, Bilaro Olu-Odo to fill the vacuum. It is our belief that the ruling house is endowed with sons who are blessed with leadership skills and qualities to move Ijesaland to greater heights. “The last time Ijesaland witnessed a similar period was 43 years ago when His Imperial Majesty, Oba Peter Adeniran Agunlejika II joined his ancestors, so it is a great privilege for us all to witness this period and if this privilege is not well utilized, will speak volume of our future as Youths of Ijesaland. “We are thereby appealing to the Ijesa Kingmakers who are the custodians of Ijesa culture, norms and traditions under the leadership of the Obaala of Ilesa to maximise their offices to uphold our ancient tradition in selecting the next occupant of Owa Obokun Adimula’s Palace as their decision will make or mar our future. “There is no gain saying the fact that there will be a lot of patronage from the interested Princes but we should all be reminded that the sacrifices of our past heroes and heroines must be well acknowledged. The Progenitor of Ijesa Obokun Kingdom and the first Owa Obokun Adimula of Ijesaland, Owa Ajibogun Onida Arara, his sons and daughters who had piloted the affairs of Ijesaland had made huge sacrifices not to be easily forgotten by either local or foreign currency or any asset that can not outlive us, their legacies must be well protected and respected. “It is expected by our fathers who are the kingmakers to be fair in handling the selection process, it is a taboo for them to have preferred or anointed candidates(s), they should be fair and just to the interested Princes regardless of their financial strengths,” Aguntasolo said. Being an ancient kingdom founded by an Odu Ifa which has since been guided by Ifa Oracle, Aguntasolo appealed to Governor Ademola Adeleke, not to allow politics to have a space in the selection process and confirmation of appointment of who-would-be the next Owa. ALSO READ FROM NIGERIAN TRIBUNE Niger Delta group tackles NUPRC over ‘unfair’ oil blocs licensing

EAGAN, Minn. (AP) — Justin Jefferson might be weary of all the safeties shadowing his every route, determined not to let the Minnesota Vikings go deep, but he's hardly angry. The double and triple coverage he continually faces, after all, is a sign of immense respect for his game-breaking ability. The strategy also simply makes sense. “I would do the same," Jefferson said. "It’s either let everybody else go off or let Justin go off. I’m going to let everybody else go off. That would be my game plan.” When the Vikings visit Chicago on Sunday, they're expecting the usual heavy dose of split-safety coverage designed to put a lid on the passing attack and force them to operate primarily underneath. “We see that every week: Teams just have different tendencies on film, and then when we go out on the field they play us totally different,” Jefferson said, later adding: “I don’t really feel like anyone else is getting played how I’m getting played.” Jefferson nonetheless is second in the NFL in receiving yards (912) behind Cincinnati's Ja'Marr Chase, his former college teammate at LSU. Last week, Jefferson set yet another all-time record by passing Torry Holt for the most receiving yards over the first five seasons of a career. Holt logged 80 regular-season games and accumulated 6,784 yards for St. Louis. Jefferson has 6,811 yards — in just 70 games. “I want to go up against those single coverages. I want to go have my opportunities to catch a deep pass downfield, just one-on-one coverage, like a lot of these other receivers get," Jefferson said. "It’s definitely difficult going up against an extra person or an extra two people, but it is what it is and the concepts that we’re drawing up and the ways that we’re trying to get me open, it definitely helps.” With fellow tight end Josh Oliver ruled out of the game on Sunday because of a sprained ankle, T.J. Hockenson is certain to have his heaviest workload since returning from knee surgery four weeks ago. He's also certain that Jefferson will continue to see persistent double-teams. “It puts it on us to make some plays and do some things to get them out of that,” Hockenson said. Vikings coach Kevin O'Connell has been forced to dig deeper into the vault of play designs and game plans to help keep quarterback Sam Darnold and the offense on track. O'Connell said after Minnesota's 12-7 win at Jacksonville, when Darnold threw three interceptions to precipitate a safer strategy down the stretch, that he superseded his play-calling role with the wisdom of a head coach to help win that game. "Not just the egomaniac of wanting to score points and constantly show everybody how smart we are. There was a mode that I think you have to go into sometimes to ensure a victory,” O'Connell said on his weekly show on KFAN radio. Taking what the defense gives is usually the shrewdest strategy. “You’ve got to really implement some new things and some things that maybe you didn’t come across during your early coaching years whether as a coordinator or position coach or even when you’re responsible for a small area of the game plan as a younger coach," O'Connell said. "You really have to kind of look outside the lens of always what you see on tape.” AP NFL: https://apnews.com/hub/NFLThe Indian Space Research Organisation (ISRO) announced that it has reached a significant milestone in the Gaganyaan Programme, with the first solid motor segment moved from the production plant to the launch complex. The space agency said, "India's human spaceflight dreams are taking shape!" In a post on the social media platform X, ISRO stated, "A significant milestone for the Gaganyaan Programme! The first solid motor segment has been moved from the production plant to the launch complex, marking a key step towards the HLVM3 G1 flight." In September, ISRO Chairman S Somanath said that efforts were underway to launch India's first human spaceflight programme, Gaganyaan, by the end of this year. "Gaganyaan is ready for launch; we are trying to launch it by the end of this year," Somanath had said. The Gaganyaan Programme, approved in December 2018, envisages human spaceflight to Low Earth Orbit (LEO) and the establishment of technologies required for a long-term Indian human space exploration endeavour. On 18 September, the Cabinet approved the Chandrayaan-4 mission to the Moon. This mission aims to develop and demonstrate technologies to return to Earth after a successful lunar landing, as well as collect and analyse Moon samples on Earth. The Chandrayaan-4 mission will achieve foundational technologies and capabilities needed for an eventual Indian landing on the Moon (planned by 2040) and a safe return to Earth. Key technologies for docking, undocking, landing, safe return, and lunar sample collection and analysis will be demonstrated. The central government's expanded vision for the Indian space programme during the Amrit Kaal includes an Indian Space Station (Bharatiya Antariksh Station) by 2035 and an Indian landing on the Moon by 2040. (Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)

The Boston Red Sox have added another relief pitcher to their roster in a Christmas Eve trade with the Minnesota Twins. The Twins are sending left-hander Jovani Morán to the Red Sox in exchange for catcher/infielder Mickey Gasper. The today acquired LHP Jovani Morán from the Minnesota Twins, in exchange for C/INF Mickey Gasper. Boston’s 40-man roster is now at 39. — Red Sox (@RedSox) Morán missed all of the 2024 season due to Tommy John surgery. He last pitched for the Twins in 2023, posting a 2-2 record, a 5.31 ERA, a 1.46 WHIP, 48 strikeouts and 27 walks over 42 1/3 innings. Morán has made a total of 43 appearances (zero starts) since making his Twins debut in 2021. Gasper played in 13 games for the Red Sox this past season. He tallied zero hits in 18 at-bats with four walks and eight strikeouts. The Red Sox previously acquired (via trade), (free agency), (free agency) and (free agency) earlier in the offseason.